OncoDiag

About

OncoDiag is a French biotechnology company founded in 2013 and based in Normandy. The company specializes in developing and marketing non-invasive diagnostic tests aimed at early cancer detection, screening, diagnosis, and monitoring, particularly for bladder, prostate, and colorectal cancers. OncoDiag is led by co-founder and CEO Claude Hennion and employs a small team of experienced professionals in urology and oncology. The company's product portfolio includes Urodiag®, a urine-based test for monitoring non-muscle invasive bladder cancer; Prostadiag®, a tissue-based test for predicting localized prostate cancer; and Colodiag®, a blood-based test for colorectal cancer screening. These innovative tests are designed to reduce the need for invasive procedures, improving patient care and potentially lowering healthcare costs. OncoDiag has received recognition for its contributions to health technology and has secured funding to support its commercialization efforts.